BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today that an independent data review committee (IDRC) has completed a review of the first interim analysis data from the Phase 2b seliciclib APPRAISE study. The IDRC assessed the safety profile of seliciclib and recommended that the study continue after reviewing data from 173 patients with previously-treated non-small cell lung cancer (NSCLC), of whom 45 proceeded into the blinded portion of the study and were randomized to receive either seliciclib or best supportive care.
